Gel filtration of supernatant fluids, from the wild-type Clostridium perfringens, strain CN3870, and several of the mutants and revertants derived from this strain, showed that these mutants failed to produce detectable amounts of the I and II forms of both hemagglutinin and sialidase activities. However, they still produced sialidase III activity. The revertants tested had regained the ability to produce approximately wild-type levels of the I and II forms of both activities. These results show that there is a direct relationship between the production of the I form of hemagglutinin and sialidase activities and the production of the II form of these biologically active proteins. Models that explain the genetic basis for these results are discussed.
In the preceding publication (4) it is shown that the wild-type Clostridium perfringens, strain CN3870, produced three mucopolysaccharide N-acetylneuraminylhydrolase (EC 3.2.1.18) (sialidase or neuraminidase) enzymes designated as sialidases I, II, and III in order of decreasing molecular weight. Sialidase I and II activities were associated with hemagglutinin I and II activities, respectively. Gel filtration, ion exchange chromatography, and polyacrylamide gel electrophoresis failed to separate sialidase I activity from hemagglutinin I activity or sialidase II activity from hemagglutinin II activity. It was suggested (4) that, for both the I and II forms, hemagglutinin and sialidase activities were associated together in protein compexes. It was not known if there was any relationship between the I and II complexes. In an earlier publication (3) we reported the isolation of a number of mutants, derived from strain CN3870, that produced reduced levels of hemagglutinin and sialidase activities. From one of these mutants, CM165, revertants that regained the ability to produce active hemagglutinin and sialidase were isolated.
It was decided to examine the gel filtration behavior of the activities present in several of these mutants and revertants with the aim of identifying the specific hemagglutinin and sialidase activities affected by the mutations and investigating the relationship between the I and II hemagglutinin-sialidase complexes. This paper reports the results of these investigations.
MATERIALS AND METHODS
Bacteria and materials. All mutant and revertant strains used in these studies were derived from C. perfringens strain CN3870. The growth, maintenance, derivation, and phenotype of all strains, as well as preparation of media, were as previously described (3) . MacLennan broth (MB) was used instead of fructose-Trypticase soy broth for reasons previously discussed (3) . All reagents and materials were from sources previously described (3, 4) .
Estimation of hemagglutinin and sialidase activities and protein. Hemagglutinin and sialidase activities were estimated as previously described (2) except that, unless otherwise stated, the sialidase incubation was carried out at pH 5.5. The number of hemagglutinin units was equal to the reciprocal of the end point dilution and was expressed as the number of units per milliliter of sample. One unit of sialidase activity was defined as the amount of enzyme required to hydrolyze 1 ,umol of N-acetylneuraminic acid per min from al-acid glycoprotein under the conditions of the assay. The protein content of column fractions was followed by determining the absorbance at 280 nm. All spectrophotometric determinations were made using a Zeiss PMQ II spectrophotometer.
Gel filtration on Sephadex G-200. Samples (5 ml) of supernatant fluid were applied to and eluted from Sephadex G-200 as previously described (4). The column was eluted at 4 C, at a flow rate of 18 ml/h, with tris(hydroxymethyl)aminomethane-hydrochloride buffer (0.02 M, pH 7.2) containing 0.15 M KCI.
Preparation of supernatant fluid. For each strain, 2 ml of a 2-h MB culture was subcultured into 15 ml of MB medium and incubated for 6 h at 37 C. After centrifugation for 15 min at 1,500 x g, the supernatant fluid was removed and treated as required.
RESULTS
It was previously shown (4) that sialidases I and II were inactive at pH 4 all strains was asayed at pH 5.5, and fractions derived from the following strains were also assayed at pH 4.0 to detect sialidase III activity. The latter strains were: the wild-type CN3870; a group C mutant (2), CM165; a group A revertant, CM213; and a group B revertant, CM207. Fractions derived from strains CN3870, CM211, and CM213 were also assayed for hemagglutinin activity. This was not possible with CM207, the only other strain tested here that produced detectable hemagglutinin activity, as its activity was too low to be detected because of dilution during chromatography. The supernatant fluid from an MB culture of strain CN3870 had approximately the same levels of hemagglutinin and sialidase activities as the fructose-Trypticase soy broth supernatant fluid examined previously by chromatography on Sephadex G-200 (4). However, the distribution ofboth activities between the I and II forms was different. The elution profile of the latter showed that the predominant activities were hemagglutinin I and sialidase I (4). In contrast, the elution profile of the MB supernatant fluid showed that the major sialidase activity was now sialidase II, with a shoulder of sialidase I, and that hemagglutinin was now spread in a plateau of activity covering the hemagglutinin I and II regions (Fig. 1) . The explanation for these results is not known and these effects were not studied further. When the fractions obtained in the MB experiment were assayed for sialidase activity at pH 4.0, a small peak of sialidase III activity was detected, thus demonstrating the presence of this enzyme in supernatant fluids derived from strain CN3870.
Chromatography of supernatant fluid from an MB culture of strain CM165, a mutant producing low levels of sialidase activity but no detectable hemagglutinin activity, showed that this strain did not produce detectable levels of the I and II forms of either activity (Fig. 2) . However, sialidase III activity was still present, as confirmed by the coincidence of the activity profiles obtained at pH 5.5 and 4.0. Strains CM156 and CM209, both with hemagglutinin and sialidase phenotypes identical to strain CM165, gave elution profiles similar to that obtained from the latter strain, except that these fractions were not assayed for sialidase activity at pH 4.0. In all three strains sialidase III activity was the only sialidase activity detected.
Chromatography of supernatant fluid from MB cultures of strain CM213, a revertant that regained the ability to produce hemagglutinin and sialidase activities, showed that this strain produced approximately wild-type levels of the I and II forms of both activities. Sialidase III activity was also present (Fig. 3) . Both hemagglutinin and sialidase activities were resolved into a major peak of the II form, together with a smaller peak of the I form. Strain CM211, which had a hemagglutinin and sialidase phenotype identical to strain CM213, gave similar elution profiles except that these fractions were not assayed for sialidase activity at pH 4.0. Strain CM207, a revertant producing hemagglutinin and sialidase activities at levels significantly lower than wild type, also gave an elution profile similar to that of strain CM213, except that there was a shoulder of sialidase activity at pH 5.5 which corresponded to the peak of sialidase III activity observed at pH 4.0 (Fig. 4) .
DISCUSSION
The results presented in this paper show that the hemagglutinin-reduced mutants CM165 and CM156 failed to produce detectable amounts of the I or II active forms of either hemagglutinin or sialidase. However, they still produced sialidase III activity, although the levels were less than those of the wild-type CN3870. Strains CM211 and CM213, both derived from strain CM165, were revertants that regained the ability to produce hemagglutinin and sialidase activities. They also produced approximately wild-type levels of sialidase III activity. Gel filtration experiments revealed that these strains had regained the ability to produce the I and II forms of both activities in approximately the same proportions as in the wild type. Another revertant, CM207, produced more hemagglutinin and sialidase activity than its hemagglutinin-reduced parent but not as much activity as the wild type. Gel filtration showed that it also regained the ability to produce both sialidase I and II activities. It is likely that the other partially reduced mutants and revertants described previously (3) also produced reduced levels of both active forms.
The phenotypes of the strains reported previously (3) were designated on the basis of their overall hemagglutinin and sialidase activities. The identification of different molecular forms of these activities (4), together with the experiments reported in this paper, now enables a more precise phenotypic designation of the strains studied in this report. All the residual sialidase activity from strains CM156, CM165, and CM209, which were originally designated Hgn-Sldr d, was in the sialidase III form. These strains are therefore now designated as HgnI-SldI-HgnI1-SldII-SldIIIred ( Table 2 ).
The results, reported both in this paper and in an earlier publication (3), show that a single point mutation can affect the expression of both hemagglutinin and sialidase I and hemagglutinin and sialidase II activities concomitantly. This mutation also affects the expression of sialidase III activity but not to the same extent. Strain CM171 was the only strain previously designated (3) as Hgn-Sld-. It is possible that this strain carries two mutations, one in a gene affecting the expression of hemagglutinin and sialidase I and II activities and the other in a separate gene affecting the expression of sialidase III activity only. The biochemical data reported previously (4) and the results presented here all provide evidence that sialidase III is not a monomeric form of the I and II proteins. It would be of interest to attempt the isolation of sialidase III mutants, by screening for mutants producing supernatant fluids that had no sialidase activity at pH 4.0 in acetate buffer, to see if such mutants produced altered forms of the I and II activities.
Two models are proposed that could explain the genetic basis for the observations reported in our studies. In these models it is assumed that sialidase III is not structurally related to the I and II proteins. For simplification, it will be initially assumed that only one of the I and II molecular forms is produced. Hypotheses will then be presented to account for the presence of two forms of both hemagglutinin and sialidase activities.
The first model proposes that there is a gene, mutations in which coordinately affect the expression of the separate structural genes coding for structurally distinct, noninteracting, hemagglutinin and sialidase proteins. The hemagglutinin reduced mutants would have arisen through mutations in this gene, rather than in the structural genes, because mutations in the latter would result in mutants that are only altered in the expression of one activity. The fact that Hgn-Sld+ mutants were not found in these studies and that Hgn+Sld-strains were not reported previously (1) The second model proposes that hemagglutinin and sialidase activities are associated in a protein complex. The term complex does not distinguish between an aggregate of different polypeptides, which includes structurally distinct hemagglutinin and sialidase subunits coded for by separate structural genes, or a single polypeptide that contains both activities and is coded for by a single structural gene. The model suggests that the hemagglutinin-reduced mutants would have arisen through mutations in a structural gene coding for an essential subunit of the complex such that either no protein at all was produced or the protein was altered so that it was inactive. It predicts that hemagglutinin and sialidase activities cannot be separated by biochemical separation techniques. If the complex is made up of hemagglutinin and sialidase subunits, then it is necessary to postulate further that it is only active ; 0 1 M~o o l o when they are combined and that the subunits themselves are inactive. Otherwise, it would not be possible for a mutation in a structural gene coding for a hemagglutinin subunit to affect sialidase activity, and vice-versa. It is also necessary to postulate that, if a mutation results in the production of a subunit that is altered such that it is inactive even when complexed with the normal subunit, then this also results in the formation of a complex that is not active for either activity. The mutations reported could have been in either of the structural genes. They may have resulted in the production of either an inactive complex or only one of the normal inactive subunits.
A simpler version of the second model is that the complex is in fact a single polypeptide, having both hemagglutinin and sialidase activities, that may or may not act by a common active site. The biochemical data reported in the preceding paper (4) support either version of the second model, rather than the first model, since the separation techniques used failed to separate the respective hemagglutinin and sialidase activities.
The presence of two forms of hemagglutinin and sialidase can be incorporated by postulating either that the hemagglutinin and sialidase I complex is a polymer of the hemagglutinin and sialidase II complex, or that they are not structurally related. If the former is the case, then a mutation resulting in an inactive II complex must also affect the I complex, assuming that the same active sites are involved in each complex. Alternatively, if the complexes are not structurally related, then their expression must be concomitantly influenced by mutations in another gene. The occurrence of mutants that produce only one active complex is therefore postulated. No such mutants were observed, although it is not certain that they would have been detected by the screening techniques used. In summary, the results at this stage are most compatible with the theory that hemagglutinin and sialidase activities reside on the one protein, HgnSldII, that aggregates to form the HgnSldI protein, which retains both activities. The alternative model is not completely ruled out by our results. Neither of the models presented here explains the relationship between the production of hemagglutinin and sialidase I and II activities and either sporulation, the production of phospholipase C activity, or the production of sialidase III activity. They also do not attempt to explain how the distribution of both hemagglutinin and sialidase activities between the I and II forms is controlled. Some, or all, of the above effects may be due to either extragenic effects of an altered gene product or polarity effects in genes adjacent to the gene carrying the mutation. The development of a more sophisticated genetic system for studying this organism should provide a means of investigating these relationships.
